1887

Abstract

To understand the prospects for human papillomavirus (HPV) mass vaccination in the setting of a developing country, we studied the co-occurrence of seropositivity to multiple high-risk (hr) HPV types among HIV-positive and HIV-negative Ugandan women. Our seroepidemiological study was conducted among 2053 women attending antenatal clinics. Sera were analysed for antibodies to eight hrHPV types of the α-7 (18/45) and α-9 (16/31/33/35/52/58) species of HPV by using a multiplex serology assay. Our results show that seropositivity for greater than one hrHPV type was as common (18 %) as for a single type (18 %). HIV-positive women had higher HPV16, HPV18 and HPV45 seroprevalences than HIV-negative women. In multivariate logistic regression analysis, age (>30 years) and level of education (secondary school and above) reduced the risk, whereas parity (>5) and HIV-positivity increased the risk for multiple hrHPV seropositivity. However, in stepwise logistic regression analyses, HIV-status remained the only independent, stand-alone risk factor [odds ratio (OR) 1.7, 95 % confidence interval (CI) 1.0–2.8). On the other hand, the risk of HPV16 or HPV18 seropositive women, as compared to HPV16 or HPV18 seronegative women, for being seropositive to other hrHPV types was not significantly different when they were grouped by HIV-status (OR 12, 95 % CI 4.5–32 versus OR 22, 95 % CI 15–31 and OR 58, 95 % CI 14–242 versus OR 45, 95 % CI 31–65). In conclusion, seropositivity to HPV16, HPV18 and to non-vaccine hrHPV types is common in Ugandan women, suggesting that there is little natural cross-protective immunity between the types. HIV-positivity was an independent, stand-alone, albeit moderate risk factor for multiple hrHPV seropositivity. HPV mass vaccination may be the most appropriate method in the fight against cervical cancer in the Ugandan population.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.035923-0
2011-12-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/92/12/2776.html?itemId=/content/journal/jgv/10.1099/vir.0.035923-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam V. , Kibur M. , Wang Z. , Koskela P. , Pukkala E. , Schiller J. , Lehtinen M. , Dillner J. . ( 1998; ). Stability over time of serum antibody levels to human papillomavirus type 16. . J Infect Dis 177:, 1710–1714. [CrossRef] [PubMed]
    [Google Scholar]
  2. Ault K. A. . Future II Study Group ( 2007; ). Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. . Lancet 369:, 1861–1868.[CrossRef]
    [Google Scholar]
  3. Banura C. , Franceschi S. , van Doorn L. J. , Arslan A. , Kleter B. , Wabwire-Mangen F. , Mbidde E. K. , Quint W. , Weiderpass E. . ( 2008a; ). Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. . Int J Cancer 123:, 2180–2187. [CrossRef] [PubMed]
    [Google Scholar]
  4. Banura C. , Franceschi S. , Doorn L. J. , Arslan A. , Wabwire-Mangen F. , Mbidde E. K. , Quint W. , Weiderpass E. . ( 2008b; ). Infection with human papillomavirus and HIV among young women in Kampala, Uganda. . J Infect Dis 197:, 555–562. [CrossRef] [PubMed]
    [Google Scholar]
  5. Banura C. , Sandin S. , van Doorn L. J. , Quint W. , Kleter B. , Wabwire-Mangen F. , Mbidde E. K. , Weiderpass E. . ( 2010; ). Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. . Infect Agent Cancer 5:: 7. [CrossRef] [PubMed]
    [Google Scholar]
  6. Blossom D. B. , Beigi R. H. , Farrell J. J. , Mackay W. , Qadadri B. , Brown D. R. , Rwambuya S. , Walker C. J. , Kambugu F. S. et al. & other authors ( 2007; ). Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. . J Med Virol 79:, 758–765. [CrossRef] [PubMed]
    [Google Scholar]
  7. Brown D. R. , Kjaer S. K. , Sigurdsson K. , Iversen O. E. , Hernandez-Avila M. , Wheeler C. M. , Perez G. , Koutsky L. A. , Tay E. H. et al. & other authors ( 2009; ). The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. . J Infect Dis 199:, 926–935. [CrossRef] [PubMed]
    [Google Scholar]
  8. Carter J. J. , Koutsky L. A. , Hughes J. P. , Lee S. K. , Kuypers J. , Kiviat N. , Galloway D. A. . ( 2000; ). Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. . J Infect Dis 181:, 1911–1919. [CrossRef] [PubMed]
    [Google Scholar]
  9. Clifford G. M. , Gonçalves M. A. , Franceschi S. . HPV and HIV Study Group ( 2006; ). Human papillomavirus types among women infected with HIV: a meta-analysis. . AIDS 20:, 2337–2344. [CrossRef] [PubMed]
    [Google Scholar]
  10. Clifford G. M. , Shin H. R. , Oh J. K. , Waterboer T. , Ju Y. H. , Vaccarella S. , Quint W. , Pawlita M. , Franceschi S. . ( 2007; ). Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. . Cancer Epidemiol Biomarkers Prev 16:, 1874–1879. [CrossRef] [PubMed]
    [Google Scholar]
  11. Clifton D. . ( 2009; ). Combating cross-generational sex in Uganda. . Washington DC:: Population Reference Bureau;. www.prb.org/Articles/2009/crossgenerationalsex.aspx (accessed January 2010).
  12. De Vuyst H. , Lillo F. , Broutet N. , Smith J. S. . ( 2008; ). HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. . Eur J Cancer Prev 17:, 545–554. [CrossRef] [PubMed]
    [Google Scholar]
  13. Dillner J. , Kallings I. , Brihmer C. , Sikström B. , Koskela P. , Lehtinen M. , Schiller J. T. , Sapp M. , Mårdh P. A. . ( 1996; ). Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. . J Infect Dis 173:, 1394–1398. [CrossRef] [PubMed]
    [Google Scholar]
  14. Dondog B. , Clifford G. M. , Vaccarella S. , Waterboer T. , Unurjargal D. , Avirmed D. , Enkhtuya S. , Kommoss F. , Wentzensen N. et al. & other authors ( 2008; ). Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. . Cancer Epidemiol Biomarkers Prev 17:, 1731–1738. [CrossRef] [PubMed]
    [Google Scholar]
  15. Ho G. Y. , Studentsov Y. , Hall C. B. , Bierman R. , Beardsley L. , Lempa M. , Burk R. D. . ( 2002; ). Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. . J Infect Dis 186:, 737–742. [CrossRef] [PubMed]
    [Google Scholar]
  16. Ho G. Y. , Studentsov Y. Y. , Bierman R. , Burk R. D. . ( 2004; ). Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. . Cancer Epidemiol Biomarkers Prev 13:, 110–116. [CrossRef] [PubMed]
    [Google Scholar]
  17. Kaasila M. , Koskela P. , Kirnbauer R. , Pukkala E. , Surcel H.-M. , Lehtinen M. . ( 2009; ). Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. . Int J Cancer 125:, 2166–2172. [CrossRef] [PubMed]
    [Google Scholar]
  18. Katahoire R. A. , Jitta J. , Kivumbi G. , Murokora D. , Arube W. J. , Siu G. , Arinaitwe L. , Bingham A. , Mugisha E. et al. & other authors ( 2008; ). An assessment of the readiness for introduction of the HPV vaccine in Uganda. . Afr J Reprod Health 12:, 159–172.[PubMed]
    [Google Scholar]
  19. Kibur M. , Koskela P. , Dillner J. , Leinikki P. , Saikku P. , Lehtinen M. , Hakama M. . ( 2000; ). Seropositivity to multiple sexually transmitted infections is not common. . Sex Transm Dis 27:, 425–430. [CrossRef] [PubMed]
    [Google Scholar]
  20. Kizito D. , Woodburn P. W. , Kesande B. , Ameke C. , Nabulime J. , Muwanga M. , Grosskurth H. , Elliott A. M. . ( 2008; ). Uptake of HIV and syphilis testing of pregnant women and their male partners in a programme for prevention of mother-to-child HIV transmission in Uganda. . Trop Med Int Health 13:, 680–682. [CrossRef] [PubMed]
    [Google Scholar]
  21. Kjellberg L. , Wang Z. , Wiklund F. , Edlund K. , Angström T. , Lenner P. , Sjöberg I. , Hallmans G. , Wallin K. L. et al. & other authors ( 1999; ). Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. . J Gen Virol 80:, 391–398.[PubMed]
    [Google Scholar]
  22. Merikukka M. , Kaasila M. , Namujju P. B. , Palmroth J. , Kirnbauer R. , Paavonen J. , Surcel H. M. , Lehtinen M. . ( 2011; ). Differences in incidence and co-occurrence of vaccine and non-vaccine human papillomavirus (HPV) types in Finnish population before HPV mass vaccination suggest competitive advantage for HPV33. . Int J Cancer 128:, 1114–1119. [CrossRef] [PubMed]
    [Google Scholar]
  23. Michael K. M. , Waterboer T. , Pfister H. , Gariglio M. , Majewski S. , Favre M. , Pawlita M. . ( 2010; ). Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. . J Invest Dermatol 130:, 841–848. [CrossRef] [PubMed]
    [Google Scholar]
  24. Molano M. , Van den Brule A. , Plummer M. , Weiderpass E. , Posso H. , Arslan A. , Meijer C. J. , Muñoz N. , Franceschi S. . HPV Study Group ( 2003; ). Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. . Am J Epidemiol 158:, 486–494. [CrossRef] [PubMed]
    [Google Scholar]
  25. Moscicki A. B. , Ellenberg J. H. , Farhat S. , Xu J. . ( 2004; ). Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. . J Infect Dis 190:, 37–45. [CrossRef] [PubMed]
    [Google Scholar]
  26. Mpairwe H. , Muhangi L. , Namujju P. B. , Kisitu A. , Tumusiime A. , Muwanga M. , Whitworth J. A. , Onyango S. , Biryahwaho B. , Elliott A. M. . ( 2005; ). HIV risk perception and prevalence in a program for prevention of mother-to-child HIV transmission: comparison of women who accept voluntary counseling and testing and those tested anonymously. . J Acquir Immune Defic Syndr 39:, 354–358. [CrossRef] [PubMed]
    [Google Scholar]
  27. Namujju P. B. , Surcel H.-M. , Kirnbauer R. , Kaasila M. , Banura C. , Byaruhanga R. , Muwanga M. , Mbidde E. K. , Koskela P. , Lehtinen M. . ( 2010; ). Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. . Scand J Infect Dis 42:, 522–526. [CrossRef] [PubMed]
    [Google Scholar]
  28. Namujju P. B. , Hedman L. , Hedman K. , Banura C. , Mbidde E. K. , Kizito D. , Byaruhanga R. N. , Muwanga M. , Kirnbauer R. et al. & other authors ( 2011; ). Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence. . BMC Res Notes 4:, 170. [CrossRef] [PubMed]
    [Google Scholar]
  29. Odida M. , de Sanjosé S. , Quint W. , Bosch X. F. , Klaustermeier J. , Weiderpass E. . ( 2008; ). Human papillomavirus type distribution in invasive cervical cancer in Uganda. . BMC Infect Dis 8:, 85. [CrossRef] [PubMed]
    [Google Scholar]
  30. Paavonen J. , Naud P. , Salmerón J. , Wheeler C. M. , Chow S. N. , Apter D. , Kitchener H. , Castellsague X. , Teixeira J. C. et al. & other authors ( 2009; ). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. . Lancet 374:, 301–314. [CrossRef] [PubMed]
    [Google Scholar]
  31. Palmroth J. , Namujju P. , Simen-Kapeu A. , Kataja V. , Surcel H.-M. , Tuppurainen M. , Yliskoski M. , Syrjänen K. , Lehtinen M. . ( 2010; ). Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. . Scand J Infect Dis 42:, 379–384. [CrossRef] [PubMed]
    [Google Scholar]
  32. Parkin D. M. , Whelan S. L. , Ferlay J. , Teppo L. , Thomas D. . (editors) ( 2002; ). Cancer Incidence in Five Continents, vol. VIII, , edn 155.. Lyon, France:: IARC Scientific Publication;.
    [Google Scholar]
  33. Safaeian M. , Kiddugavu M. , Gravitt P. E. , Gange S. J. , Ssekasanvu J. , Murokora D. , Sklar M. , Serwadda D. , Wawer M. J. et al. & other authors ( 2008; ). Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. . Cancer Epidemiol Biomarkers Prev 17:, 1300–1307. [CrossRef] [PubMed]
    [Google Scholar]
  34. Serwadda D. , Wawer M. J. , Shah K. V. , Sewankambo N. K. , Daniel R. , Li C. , Lorincz A. , Meehan M. P. , Wabwire-Mangen F. , Gray R. H. . ( 1999; ). Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. . J Infect Dis 180:, 1316–1319. [CrossRef] [PubMed]
    [Google Scholar]
  35. Slaymaker E. , Bwanika J. B. , Kasamba I. , Lutalo T. , Maher D. , Todd J. . ( 2009; ). Trends in age at first sex in Uganda: evidence from Demographic and Health Survey data and longitudinal cohorts in Masaka and Rakai. . Sex Transm Infect 85: (Suppl. 1), i12–i19. [CrossRef] [PubMed]
    [Google Scholar]
  36. Soto-De Leon S. , Camargo M. , Sanchez R. , Munoz M. , Perez-Prados A. , Purroy A. , Patarroyo M. E. , Patarroyo M. A. . ( 2011; ). Distribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. . PLoS ONE 6:, e14705. [CrossRef] [PubMed]
    [Google Scholar]
  37. Syrjänen S. , Waterboer T. , Sarkola M. , Michael K. , Rintala M. , Syrjänen K. , Grenman S. , Pawlita M. . ( 2009; ). Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. . J Gen Virol 90:, 1515–1526. [CrossRef] [PubMed]
    [Google Scholar]
  38. Trottier H. , Mahmud S. , Costa M. C. , Sobrinho J. P. , Duarte-Franco E. , Rohan T. E. , Ferenczy A. , Villa L. L. , Franco E. L. . ( 2006; ). Human papillomavirus infections with multiple types and risk of cervical neoplasia. . Cancer Epidemiol Biomarkers Prev 15:, 1274–1280. [CrossRef] [PubMed]
    [Google Scholar]
  39. Wabinga H. , Ramanakumar A. V. , Banura C. , Luwaga A. , Nambooze S. , Parkin D. M. . ( 2003; ). Survival of cervix cancer patients in Kampala, Uganda: 1995–1997. . Br J Cancer 89:, 65–69. [CrossRef] [PubMed]
    [Google Scholar]
  40. Waterboer T. , Sehr P. , Michael K. M. , Franceschi S. , Nieland J. D. , Joos T. O. , Templin M. F. , Pawlita M. . ( 2005; ). Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. . Clin Chem 51:, 1845–1853. [CrossRef] [PubMed]
    [Google Scholar]
  41. Waterboer T. , Sehr P. , Pawlita M. . ( 2006; ). Suppression of non-specific binding in serological Luminex assays. . J Immunol Methods 309:, 200–204. [CrossRef] [PubMed]
    [Google Scholar]
  42. Woodman C. B. , Collins S. , Winter H. , Bailey A. , Ellis J. , Prior P. , Yates M. , Rollason T. P. , Young L. S. . ( 2001; ). Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. . Lancet 357:, 1831–1836. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.035923-0
Loading
/content/journal/jgv/10.1099/vir.0.035923-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error